Literature DB >> 2686411

Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections.

G M Trenholme1, B A Schmitt, J Spear, L C Gvazdinskas, S Levin.   

Abstract

This study determined the efficacy of intravenous ciprofloxacin in the treatment of institutionalized patients with lower respiratory tract infections. Hospitalized adults with hospital/nursing home-acquired pneumonia were randomly assigned to receive either intravenous ciprofloxacin or ceftazidime. When deemed feasible, therapy was changed to oral ciprofloxacin for patients who received ciprofloxacin intravenously or to any alternative oral therapy for patients who received ceftazidime. All 23 patients who received ciprofloxacin had a favorable response versus 15 of 21 patients who received ceftazidime (p less than 0.025). One patient with a favorable response to ceftazidime developed a superinfection and one patient had a relapse during subsequent alternative oral therapy. However, patients who received ceftazidime were more severely ill than those who received ciprofloxacin on the basis of APACHE II scores.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686411     DOI: 10.1016/0002-9343(89)90037-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

3.  Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia.

Authors:  R Saginur; G Garber; G Darling; S Shafran; W Cameron; G Jones; F Auclair
Journal:  Can J Infect Dis       Date:  1997-03

Review 4.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

6.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs.

Authors:  M J Novotny; D H Shaw
Journal:  Can J Vet Res       Date:  1991-04       Impact factor: 1.310

Review 8.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

9.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

Review 10.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.